Directorate change

    Appointment of Ian Clark as Non-Executive Director

    January 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) ("Shire"' / the "Company")
    announces the appointment of Ian Clark as a Non-Executive Director of the
    Company with effect from the date of this announcement.

    Mr. Clark served as Chief Executive Officer and Director of Genentech Inc (part
    of the Roche Group) and Head of North American Commercial Operations for Roche
    until December 31, 2016, having held several senior strategy, operations and
    commercially focused roles since joining Genentech in 2003. Prior to this Mr.
    Clark held various senior operational, sales and marketing roles in other
    pharmaceutical and healthcare companies. He is currently appointed as a
    Non-Executive Director of TerraVia Holdings Inc. where he serves as Chairman of
    the Compensation Committee and as a member of the Nominating and Corporate
    Governance Committee.

    Susan Kilsby, Shire's Chairman, commented: "We are very pleased to announce
    Ian's appointment at this important time; his in-depth knowledge of the
    biotechnology sector and breadth of operational experience stand to serve Shire
    well as we look forward to growing our business and addressing unmet patient
    needs world-wide."

    Mr. Clark added: "Shire has demonstrated commitment to being the global leader
    in rare diseases and to delivering value to its patients, physicians,
    shareholders and other stakeholders. I look forward to working with Susan and
    the rest of the Board in pursuing a successful future for the Company."

    Oliver Strawbridge
    Senior Assistant Company Secretary

    For further information please contact:

    Investor Relations                                                           
                                                                                 
    Ian Karp                        ikarp@shire.com            +1 781 482 9018   
                                                                                 
    Robert Coates                   rcoates@shire.com          +44 1256 894874   
                                                                                 
    Media                                                                        
                                                                                 
    Lisa Adler                      lisa.adler@shire.com       +1 617 588 8607   
                                                                                 
    Debbi Ford                      debbi.ford@shire.com       +1 617 949 9083   

    NOTES TO EDITORS

    No further information is required to be disclosed pursuant to 9.6.13R of the
    UK Listing Rules.

    About Shire

    Shire is the leading global biotechnology company focused on serving people
    with rare diseases and other highly specialized conditions. We strive to
    develop best-in-class products, many of which are available in more than 100
    countries, across core therapeutic areas including Hematology, Immunology,
    Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal /
    Internal Medicine / Endocrine and Hereditary Angioedema; and a growing
    franchise in Oncology.

    Our employees come to work every day with a shared mission: to develop and
    deliver breakthrough therapies for the hundreds of millions of people in the
    world affected by rare diseases and other high-need conditions, and who lack
    effective therapies to live their lives to the fullest.

    www.shire.com